Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
Business Of Biotech
00:00
The Value of Years Spending Observation and Researching in the Biotech Industry
George, we're running short on time here but I got a couple more questions for you before. You raised $150 million in that IPO back in April of last year I think that happened on the back of a spec deal with helix acquisitions and pipe. So in the time we have here if you could just kind of walk us through your reflections on that what was good but was bad what was ugly about that experience. Obviously more good than bad and ugly but give us the insider's view.
Transcript
Play full episode
